GlassScriptPhysician profile
Praveen Jinnur
NPI 1467755165
$2,942.47
in general payments reported to CMS, 2019-2025
31 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.27 · 2022: $218 · 2023: $575 · 2024: $680 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.17 |
| Education | $190.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $566.85 | 2022-2025 | Dupixent, Evkeeza |
| Astrazeneca Pharmaceuticals LP | $403.90 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Insmed, INC. | $266.41 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.65 | 2022-2025 | Ofev |
| Grifols USA, LLC | $155.14 | 2024-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $152.19 | 2021-2024 | |
| Amgen INC. | $127.97 | 2023-2024 | Tezspire, Tavneos |
| Mallinckrodt Hospital Products INC. | $122.99 | 2023 | Acthar |
| Actelion Pharmaceuticals US, INC. | $103.98 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Baxter Healthcare | $87.33 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Harmony Biosciences LLC | $74.22 | 2025 | |
| Electromed, INC. | $70.68 | 2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $62.50 | 2025 | |
| Axsome Therapeutics, INC. | $62.01 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $56.62 | 2022-2024 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.96 | 2025 | Nucala |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.58 | 2023 | Lifevest |
| Merck Sharp & Dohme LLC | $41.02 | 2025 | Winrevair |
| Philips North America LLC | $38.42 | 2022-2023 | |
| Abiomed | $36.25 | 2025 | |
| Genzyme Corporation | $30.64 | 2025 | |
| Janssen Pharmaceuticals, INC | $28.93 | 2022 | |
| Esperion Therapeutics, INC. | $28.87 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $24.36 | 2025 | Glassia |
| Kiniksa Pharmaceuticals International, Plc | $17.80 | 2024 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $17.38 | 2022 | |
| Viatris Specialty LLC | $16.95 | 2025 | Yupelri |
| Edwards Lifesciences Corporation | $16.35 | 2023 | |
| Scpharmaceuticals INC. | $15.67 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.70 | 2024 | Edarbi |
| Paratek Pharmaceuticals, INC. | $14.15 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praveen Jinnur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.